UK-based surgical technologies developer Alesi Surgical has raised a total of €6m in funding from existing and new investors for commercial expansion of its business, as well as its Ultravision device.

European med tech venture capital companies Panakes Partners and Earlybird contributed to the new investment, alongside existing shareholders IP Group and Finance Wales.

The firm intends to use the latest funds for expansion into international markets such as the US, and for further research and development of its Ultravision technology.

The Ultravision platform is an electrostatic technology designed to eliminate surgical smoke produced by surgical cutting equipment during abdominal keyhole/laparoscopic surgery.

The technology generates a low-energy electrostatic charge and is claimed to improve the visibility for surgeons by actively clearing the smoke.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

The system is also capable of reducing the amount of cold, dry carbon dioxide gas required to create a working space inside a patient’s abdomen.

The decrease is said to benefit the patients as excessive exposure to carbon dioxide results in cardiovascular conditions, complications in anaesthesia, post-surgical pain, and longer recovery time.

"The Ultravision platform is an electrostatic technology designed to eliminate surgical smoke produced by surgical cutting equipment during abdominal keyhole/laparoscopic surgery."

Currently available in the European and Middle Eastern markets, Ultravision recently obtained approval from the US Food and Drug Administration (FDA) and the Japanese Ministry of Health.

Alesi Surgical managing director Dr Dominic Griffiths said: “Earlybird and Panakes are two highly respected European venture capital companies and, in such a competitive funding environment, their interest in Alesi and Ultravision speaks volumes for our potential.

“With the three new additions to the board, we have expanded our expertise in this market and having four corporate investors places us in a strong position for future growth.”

At the same time, Alesi Surgical appointed new board directors, including former Molnlycke Healthcare president Phil Cooper, Earlybird partner and former Ethicon Endosurgery vice-president Thom Rasche, and Panakes Partners founding partner Alessio Beverina.

Image: Alesi Surgical managing director Dr Dominic Griffiths. Photo: courtesy of Alesi Surgical Limited.